Understanding gene expression
Scattering (RLS) technology product - an RLS-based two-colour
nucleic Acid microarray toolkit for gene expression analysis.
Genicon Sciences this week launched its second Resonance Light Scattering (RLS) technology product - an RLS-based two-colour nucleic Acid microarray toolkit for gene expression analysis.
According to Genicon the toolkit is an ultra-sensitive, multi-colour assay that is capable of deriving more data from small amounts of biological material and identifying expressed genes that are undetectable by current methods - critical to clinical diagnostics and the drug discovery process.
The toolkit is part of a fully integrated detection system, the RLS Array Detection system that provides researchers with a total assay platform for gene expression analysis. The system includes the toolkit, the GSD-501 RLS detection and imaging instrument and arrayVision RLS image analysis software.
The RLS Array Detection system is available through Genicon Sciences, and will soon be available through Genicon's co-distribution partner, Qiagen.
Genicon Sciences' RLS technology is a reproducible, ultra-sensitive, non-fluorescent signal generation and detection technology based on nanometer-sized metal colloidal particles - RLS Particles - that can be used as ultra-sensitive biological labels in a variety of analytical bioassays critical in the drug discovery process and clinical diagnostics.
When illuminated with configured white light, RLS Particles generate intense, coloured, scattered light signals. The sensitivity of RLS technology, claims the company, allows researchers to analyse nucleic acids, proteins and biomarkers that are not normally detected by current standard assay microarray methods, enabling results utilising as little as 10-fold less starting material.
"Our goal is to provide open access to our RLS Technology through products that benefit and meet the needs of the life science research community," said Patrick J. Mallon, president & CEO of .Genicon Sciences. "It's exciting for us to commercialise another product that readily aids researchers in identifying and routinely studying differentially expressed genes in a manner that was not previously possible."